Exp Mol Med:雌激素受体β能够促进膀胱癌生长和入侵

2018-12-07 AlexYang MedSci原创

尽管早期研究表明了膀胱癌(BCa)在男性中要比女性中更加流行,肌肉侵入比例在女性中要比男性更高,表明了性激素可能在BCa发展过程中的不同阶段具有重要的作用。最近,有研究人员发现雌激素受体β能够增加BCa细胞增殖和入侵,具体是通过改变miR-92a调控的DAB2IP(DOC-2/DAB2互作蛋白)信号,并且通过一个抑制子阻断miR-92a表达能够部分的逆转ERβ增强的BCa细胞生长和入侵。进一步的机

尽管早期研究表明了膀胱癌(BCa)在男性中要比女性中更加流行,肌肉侵入比例在女性中要比男性更高,表明了性激素可能在BCa发展过程中的不同阶段具有重要的作用。

最近,有研究人员发现雌激素受体β能够增加BCa细胞增殖和入侵,具体是通过改变miR-92a调控的DAB2IP(DOC-2/DAB2互作蛋白)信号,并且通过一个抑制子阻断miR-92a表达能够部分的逆转ERβ增强的BCa细胞生长和入侵。进一步的机制解析发现ERβ能够通过结合到宿主基因C13orf25 5'端的启动子区域的雌激素响应元件(ERE)来增加miR-92a的转录表达水平。另外,ERβ上调miR-92a能够通过结合到其在DAB2IP 3′ UTR上的结合位点减少DAB2IP肿瘤抑制子的表达。使用体内小鼠模型的预临床研究确定了利用小分子以新鉴定的ERβ/miR-92a/DAB2IP信号途径为靶标,能够抑制BCa的恶化。

最后,研究人员指出,这些结果也许在通过靶定ERβ调控的信号途径从而更好的抑制BCa恶化的新的治疗方法开发中有帮助。

原始出处:

Zhenyu Ou, Yongjie Wang, Jinbo Chen et al. Estrogen receptor β promotes bladder cancer growth and invasion via alteration of miR-92a/DAB2IP signals. Exp Mol Med. 20 Nov 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1503492, encodeId=76091503492f2, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sun Dec 09 13:37:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609371, encodeId=ca2e16093e1ea, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Dec 09 13:37:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354793, encodeId=d066354e93cb, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Dec 08 09:18:41 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354790, encodeId=3266354e902a, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sat Dec 08 09:10:01 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354770, encodeId=1755354e7041, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Dec 07 22:58:53 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1503492, encodeId=76091503492f2, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sun Dec 09 13:37:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609371, encodeId=ca2e16093e1ea, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Dec 09 13:37:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354793, encodeId=d066354e93cb, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Dec 08 09:18:41 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354790, encodeId=3266354e902a, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sat Dec 08 09:10:01 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354770, encodeId=1755354e7041, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Dec 07 22:58:53 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
    2018-12-09 hb2008ye
  3. [GetPortalCommentsPageByObjectIdResponse(id=1503492, encodeId=76091503492f2, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sun Dec 09 13:37:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609371, encodeId=ca2e16093e1ea, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Dec 09 13:37:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354793, encodeId=d066354e93cb, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Dec 08 09:18:41 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354790, encodeId=3266354e902a, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sat Dec 08 09:10:01 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354770, encodeId=1755354e7041, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Dec 07 22:58:53 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
    2018-12-08 kafei

    学习了谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1503492, encodeId=76091503492f2, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sun Dec 09 13:37:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609371, encodeId=ca2e16093e1ea, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Dec 09 13:37:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354793, encodeId=d066354e93cb, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Dec 08 09:18:41 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354790, encodeId=3266354e902a, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sat Dec 08 09:10:01 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354770, encodeId=1755354e7041, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Dec 07 22:58:53 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
    2018-12-08 1dd8a7c5m95(暂无匿称)

    好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1503492, encodeId=76091503492f2, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sun Dec 09 13:37:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609371, encodeId=ca2e16093e1ea, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Dec 09 13:37:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354793, encodeId=d066354e93cb, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Dec 08 09:18:41 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354790, encodeId=3266354e902a, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sat Dec 08 09:10:01 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354770, encodeId=1755354e7041, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Dec 07 22:58:53 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
    2018-12-07 医者仁心5538

    学习了

    0

相关资讯

理想照进现实:氟维司群进入国家医保目录,惠及更多ER+晚期乳腺癌患者

2017年7月,国家医保目录更新,氟维司群作为唯一一个乳腺癌内分泌治疗药物,也是目前最有效的内分泌治疗药物被纳入国家医保乙类目录。在未来,氟维司群会为更多的ER+晚期乳腺癌患者带来福音。

ANN ONCOL:Palbociclib治疗雌激素受体阳性HER2阴性转移性乳腺癌

palbociclib单药治疗晚期乳腺癌的活性还未得到充分研究,只有1个临床试验的数据。但是该试验的限制之处在于患者均接受过大量的其他治疗。临床前数据表明palbociclib可以部分逆转内分泌治疗耐药,这一假说还未在临床试验中进行研究。ANN ONCOL近期发表了一篇文章,研究palbociclib单药活性,palbociclib联合在疾病进展前接受过的同一种内分泌疗法的联合治疗效果。研究的患者

PLOS ONE:肌腱病为何在女性中多发?

主要在女性中发病的肌腱病是由重复的手势和运动引起的肌肉骨骼疾病。该疾病被认为是过度使用的综合症。外部机械应力和激素水平的变化都可能影响疾病进展。

Oncogene:雌激素受体β能够促进肾细胞恶性肿瘤的恶化

之前的研究表明了雌激素受体β(ERβ)能够影响前列腺肿瘤和膀胱肿瘤的恶化,然而,它在肾细胞恶性肿瘤(RCC)中的作用仍旧处于待阐释状态。最近,有研究人员阐释了在RCC患者中,雌激素受体β的表达与总生存/无疾病生存具有负相关关系,并且还提供了相关临床证据。研究人员对机制的剖析阐释了利用雌激素受体β-shRNA以雌激素受体β为靶标和利用17β-雌二醇或者环境内分泌干扰物刺激雌激素受体β的反式激活,均能

CLIN CANCER RES:Pembrolizumab治疗雌激素受体阳性/HER2阴性晚期乳腺癌

CLIN CANCER RES近期发表了一篇文章,研究抗PD-1单抗Pembrolizumab治疗雌激素受体阳性(ER+)/HER2阴性(HER2-),PD-L1阳性的晚期乳腺癌患者的安全性和抗肿瘤活性。

Radiology:雌激素受体阳性乳腺癌复发风险?定性放射基因学组来说道说道!

乳腺癌Breast Cancer是目前全球女性中发病最高的恶性肿瘤,是一种全身性疾病,乳腺位置及乳腺癌示意图在早期即可发生腋淋巴结转移,因此在治疗策略上早期发现并阻断其转移对乳腺癌的治疗及预后具有重大的临床意义。而浸润性乳腺癌是乳腺癌的主要类型严重危害着女性的身心健康。本研究旨在评价雌激素受体阳性乳腺癌患者乳腺影像学报告和数据系统(BI-RADS)乳腺X线摄影和磁共振(MR)成像特征与乳腺复发风险